Table 3 Overview improved performance of NGS-based clonality assessment compared to the BIOMED-2/EuroClonality assay in classic Hodgkin lymphoma.

From: Clonality assessment and detection of clonal diversity in classic Hodgkin lymphoma by next-generation sequencing of immunoglobulin gene rearrangements

View full size image

  1. The clonality results are based on duplicate analysis for FF and FFPE tissue samples for both techniques. All rearrangements are detected in the presence of a polyclonal background. Colors used: green: improved performance IG-NGS (NGS) compared to BIOMED-2/GeneScan (GS), lighter shade indicates improvement (evaluable results), without detection of clonal rearrangement; blue: failed detection of clonotype by IG-NGS compared to BIOMED-2/EuroClonality (see Supplementary Fig. S7); orange: added value of FR1/2 testing, based on the GS results (see Supplementary Table S3). P polyclonal, Pirr polyclonal irregular pattern, P_LE polyclonal_less evaluable, the results are based on less than 4 interpretable IG targets and therefore potential clonal results can be missed, resulting in a molecular conclusion that may be less reliable compared to samples with interpretable results on all 4 IG targets; R clonal rearrangement, C clonal, BC biclonal, NE not evaluable, ND not done.
  2. *IGHD1/2/3/5-IGHJ and IGKV2/4/5 are not evaluable, due to suboptimal DNA quality. #IGHV-IGHD-IGHJ results on the basis of BIOMED-2 FR3 primer only. ‡IGHV-IGHD-IGHJ results on the basis of BIOMED-2 FR1, FR2, and FR3 primers. †The second clonal IGHD-IGHJ rearrangement was observed in HRS-enriched FF DNA fraction (see Supplementary Table S5).
Back to article page